EPIX retains full rights to EP-2104R; Schering decides not to exercise option

By Elaine Rigoli

Tampa, Fla., July 13 - EPIX Pharmaceuticals, Inc., which recently announced a definitive agreement to merge with Predix Pharmaceuticals Holdings, Inc., announced that Schering AG, which is undergoing a merger with Bayer AG, is not going to exercise its option for EPIX's fibrin-binding imaging agent EP-2104R.

Under the agreement, EPIX will retain full rights to the EP-2104R program.

"Although Schering has decided not to exercise its option, we intend to diligently pursue a collaboration for the continued development of EP-2104R with other potential partners. We found the images generated from the phase 2a feasibility studies of EP-2104R to be encouraging, and are excited about the potential role of EP-2104R in imaging medicine," EPIX president and chief operating officer Andrew Uprichard said in a news release.

EP-2104R is a fibrin-binding agent designed to detect blood clots using MRI. After injection, the agent localizes in fibrin, a constituent of all blood clots, allowing visualization using MRI, the release said.

EPIX, based in Cambridge, Mass, develops pharmaceuticals for imaging modalities.

Predix is a pharmaceutical company based in Lexington, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.